Overview Technical Risk & rank Results Accounts Filings Options Guidance & governance
Guidance tracker
What PPLPHARMA guided, and what came next
| Filed | What the filing says | Next results: profit YoY | Revenue | Move on the day |
|---|---|---|---|---|
| 27 Oct 2026 | Piramal Pharma filed its press release and investor presentation on unaudited standalone and consolidated results for the quarter and half year ended 30 September 2026 (Q2 and H1 FY27). Consolidated revenue from operations was ₹2,617 crores in Q2FY27 (up 28% YoY from ₹2,044 crores) and ₹4,887 crores in H1FY27 (up... NSE copy | No results filed since | ||
| 27 Oct 2026 | Piramal Pharma filed its press release and investor presentation on unaudited standalone and consolidated results for Q2 and H1 FY27 (quarter and half year ended 30 September 2026). Consolidated revenue from operations was ₹2,617 crores in Q2FY27 (up 28% YoY from ₹2,044 crores) and ₹4,887 crores in H1FY27 (up 23%... NSE copy | No results filed since | ||
| 29 Jul 2026 | Piramal Pharma filed its press release and investor presentation on unaudited standalone and consolidated results for the quarter ended 30 June 2026 (Q1 FY27). Consolidated revenue from operations rose 17% to ₹2,270 crores (Q1 FY26: ₹1,934 crores); EBITDA rose 72% to ₹285 crores, with EBITDA margin at 12.5% (8.5%... NSE copy | - | +28.1 % | +17.1 % |
| 28 Apr 2026 | Piramal Pharma Limited filed its press release and investor presentation on audited standalone and consolidated results for the quarter and year ended 31 March 2026. Q4FY26 consolidated revenue from operations was ₹2,752 Crores (flat YoY) and EBITDA was ₹507 Crores (down 16% YoY, margin 18%). Q4FY26 PAT after... NSE copy | - | +17.4 % | +0.5 % |
| 29 Jan 2026 | Piramal Pharma filed its press release and investor presentation on unaudited standalone and consolidated results for the quarter and nine months ended 31 December 2025. Consolidated Q3FY26 revenue from operations was ₹2,140 crore (down 3% YoY from ₹2,204 crore); 9MFY26 revenue was ₹6,117 crore (down 4% YoY).... NSE copy | - | - | -2.6 % |
| 28 Jul 2025 | Piramal Pharma filed its press release and investor presentation on unaudited standalone and consolidated results for the quarter ended 30 June 2025 (Q1FY26). Consolidated revenue from operations was ₹1,934 crore vs ₹1,951 crore in Q1FY25 (down 1%); EBITDA was ₹165 crore vs ₹224 crore (down 26%), with EBITDA margin... NSE copy | -539.2 % | -8.8 % | -0.5 % |
| 28 Jul 2025 | Piramal Pharma Limited filed its press release and investor presentation on unaudited standalone and consolidated results for the quarter ended 30 June 2025 (Q1FY26). Consolidated revenue from operations was ₹1,934 crores vs ₹1,951 crores in Q1FY25 (down 1%); EBITDA was ₹165 crores vs ₹224 crores, with EBITDA... NSE copy | -539.2 % | -8.8 % | -0.5 % |
| 14 May 2025 | Piramal Pharma filed its press release and investor presentation on audited standalone and consolidated results for Q4 and FY ended 31 March 2025. Consolidated revenue from operations was ₹2,754 crore in Q4FY25 (up 8% YoY) and ₹9,151 crore in FY25 (up 12% YoY). Consolidated EBITDA was ₹603 crore in Q4FY25 (up 8%)... NSE copy | - | -0.9 % | +0.6 % |
| 14 May 2025 | Piramal Pharma filed its press release and investor presentation on audited standalone and consolidated results for Q4 and FY2025 (quarter and year ended 31 March 2025), dated 14 May 2025. Consolidated FY25 revenue from operations was ₹9,151 crore, up 12% YoY; Q4FY25 revenue was ₹2,754 crore, up 8% YoY.... NSE copy | - | -0.9 % | +0.6 % |
Filings tagged as guidance, newest first (9 in all), with the company's next results after each: profit and revenue against the same quarter a year before, and the share's move on the results day. Whether the guidance was met is for the reader to judge from both; the site does not score it. The summaries are written by an AI model from the filing and can be wrong - the filing is the source.
Governance
Management, auditors, ratings and legal matters
| Filed | Kind | What the filing says |
|---|---|---|
| 28 Apr 2026 | Legal or regulatory, Management change | Board of Piramal Pharma Limited approved audited standalone and consolidated financial results for the quarter and year ended 31 March 2026, with auditor reports carrying an unmodified opinion (auditor: Suresh Surana & Associates LLP). Board re-appointed Ms. Nandini Piramal as Whole-Time Director designated as... NSE copy |
| 28 Apr 2026 | Legal or regulatory, Management change | Board of Piramal Pharma Limited approved audited standalone and consolidated financial results for the quarter and financial year ended 31 March 2026; the statutory auditor (Suresh Surana & Associates LLP) issued unmodified opinions. Board approved re-appointment of Ms. Nandini Piramal as Whole-Time Director... NSE copy |
| 16 Oct 2025 | Credit rating | Piramal Pharma Limited filed an intimation under Regulation 30 of the SEBI Listing Regulations on 16 October 2025. ICRA Limited withdrew the credit rating of [ICRA]A1+ assigned to the Company's Rs. 100 crore Commercial Paper Programme (proposed), at the Company's request. The withdrawal is because there is no open... NSE copy |
| 28 Jul 2025 | Legal or regulatory | Piramal Pharma filed its press release and investor presentation on unaudited standalone and consolidated results for the quarter ended 30 June 2025 (Q1FY26). Consolidated revenue from operations was ₹1,934 crore vs ₹1,951 crore in Q1FY25 (down 1%); EBITDA was ₹165 crore vs ₹224 crore (down 26%), with EBITDA margin... NSE copy |
| 21 Jul 2025 | Credit rating | Piramal Pharma Limited filed an intimation under Regulation 30 of the SEBI Listing Regulations dated 21 July 2025. CARE Ratings Limited upgraded the long-term bank facilities to CARE AA; Stable from CARE AA-; Positive. CARE upgraded the issuer rating and non-convertible debentures to CARE AA; Stable from CARE AA-;... NSE copy |
| 14 May 2025 | Management change | Piramal Pharma's board on 14 May 2025 approved audited standalone and consolidated results for the quarter and year ended 31 March 2025. Standalone revenue from operations for FY2025 was Rs 5,285.71 crore and net profit after tax was Rs 691.40 crore; for Q4 FY2025 revenue was Rs 1,689.80 crore and net profit was Rs... NSE copy |
| 14 May 2025 | Management change | Outcome of board meeting held on 14 May 2025: audited standalone and consolidated financial results for the quarter and year ended 31 March 2025 approved. Standalone for FY2025: revenue from operations Rs. 5,285.71 crore, net profit after tax Rs. 691.40 crore, basic EPS Rs. 5.22 (FY2024 net profit Rs. 391.22... NSE copy |
| 14 May 2025 | Management change | Board of Piramal Pharma Limited approved audited standalone and consolidated financial results for the quarter and year ended March 31, 2025, on May 14, 2025. Standalone revenue from operations for FY2025 was Rs. 5,285.71 crores and net profit after tax was Rs. 691.40 crores, versus Rs. 4,390.11 crores and Rs.... NSE copy |
| 14 May 2025 | Management change | Piramal Pharma's board on 14 May 2025 approved audited standalone and consolidated results for the quarter and year ended 31 March 2025. For Q4 FY25 (quarter ended 31 March 2025), standalone revenue from operations was Rs. 1,689.80 crore and net profit after tax was Rs. 277.27 crore; for FY25, revenue from... NSE copy |
| 28 Jan 2025 | Management change | Board of Piramal Pharma Limited approved unaudited standalone and consolidated financial results for the quarter and nine months ended 31 December 2024 on 28 January 2025. Standalone revenue from operations for Q3 FY25 was Rs. 1,248.32 crores versus Rs. 1,024.14 crores in the corresponding quarter last year;... NSE copy |
| 28 Jan 2025 | Management change | Board of Piramal Pharma Limited approved unaudited standalone and consolidated financial results for the quarter and nine months ended 31 December 2024 on 28 January 2025. Standalone revenue from operations for Q3 FY25 (quarter ended 31 Dec 2024) was Rs. 1,248.32 crores, against Rs. 1,024.14 crores in the... NSE copy |
| 08 Jan 2025 | Legal or regulatory | Piramal Pharma Limited responded to an NSE query dated 8 November 2024 on its quick results for the quarter and half year ended 30 September 2024, filed after the board meeting of 23 October 2024. The company said the results were uploaded in searchable PDF format on the NEAPS portal and that the cash flow... NSE copy |
Filings with a management change, a legal or regulatory matter or a credit rating (by their tags), or naming an auditor, a resignation or a pledge of shares; newest first (12 in all). A list of what was filed, not a judgement of the company.